Latest Earnings Results: Q1 '26
Estimated EPS
$0.00
Reported EPS
-$0.08
Surprise
-1700%
Estimated Rev
$33.72M
Reported Rev
$1.44M
Surprise
-95.72%
$SGMO Q1 '26 Earnings Results & Recap Sangamo Therapeutics expects GAAP total operating expenses to be approximately $110M to $130M in 2026, with non-GAAP expenses ranging from $100M to $120M, subject to securing adequate additional funding.
Generated by Stocktwits using AI and company-reported earnings data for Q1 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q2 '26 | -$0.07 | -- | -- | N/A |
Q1 '26 | $0.00 | -$0.08 | -1700.00% | MISSED |
Q4 '25 | $0.01 | -$0.11 | -1318.84% | MISSED |
Q3 '25 | -$0.00 | -$0.11 | -24344.44% | MISSED |
Q2 '25 | -$0.01 | -$0.08 | -694.68% | MISSED |
